Cipla Partners with Stempeutics, Launches Stem Cell Therapy for Knee Osteoarthritis
Cipla has partnered with Stempeutics to launch Ciplostem, a single-dose stem cell therapy for knee osteoarthritis. The treatment uses 25 million expanded Bone Marrow–derived Mesenchymal Stem Cells (BM-MSCs) combined with hyaluronic acid to support joint repair and pain relief.
Knee Osteoarthritis | 04/12/2025 | By Dineshwori
4Moving Biotech Secures EUR 7.6M France 2030 Grant to Advance Osteoarthritis Drug
4MB's selection is a significant endorsement, granted through a rigorous, multi-stage evaluation process by leading scientific, clinical, and technological experts.
Knee Osteoarthritis | 08/04/2025 | By Abha | 159
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy